TARA net incomeQ3 2026-$21.69M
TARA net income was -$21.69M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$13.26M a year earlier. For the full fiscal 2025 it was -$57.44M, compared with -$44.60M in fiscal 2024.
Protara Therapeutics Inc. (TARA) financials
For the twelve months ended Sep 30, 2026, Protara Therapeutics Inc. reported -$78.44M of net income.
- Net income, TTM
- -$78.44M
- EPS, diluted, TTM
- -$1.41
- Cash
- $25.15M
- Market cap
- $148.3M
FY2016FY2025
FY2016FY2025
TARA revenue and earnings growth
TARA EPSQ3 2026-$0.35
TARA diluted EPS was -$0.35 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$1.34.
TARA free cash flowQ3 2026-$19.16M
TARA free cash flow was -$19.16M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$12.46M a year earlier. For the full fiscal 2025 it was -$56.46M, compared with -$35.87M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $42.63M | $31.70M | $24.99M | $16.81M | $21.09M | $11.98M | $3.88M | $11.85M | $21.69M | $18.87M |
| Selling, general and admin | $21.92M | $17.45M | $18.62M | $20.74M | $26.40M | $22.46M | $3.95M | $9.52M | $8.68M | $9.84M |
| Operating income | -$64.55M | -$49.15M | -$43.61M | -$67.06M | -$47.49M | -$34.44M | -$7.83M | -$21.37M | -$30.36M | -$28.70M |
| Interest expense | - | - | - | - | $0 | $34.0K | - | - | - | - |
| Pre-tax income | $57.35M | $44.56M | - | - | - | - | -$14.99M | -$20.73M | -$29.96M | -$28.53M |
| Net income | -$57.44M | -$44.60M | -$40.42M | -$65.95M | -$47.25M | -$33.98M | -$7.83M | -$20.73M | -$29.96M | -$28.53M |
| EPS, basic | -$1.34 | -$2.17 | -$3.57 | -$5.86 | -$4.21 | -$4.70 | -$3.04 | -$45.80 | -$85.20 | -$68.80 |
| EPS, diluted | -$1.34 | -$2.17 | -$3.57 | -$5.86 | -$4.21 | -$4.70 | -$3.04 | -$45.80 | -$85.20 | -$68.80 |
| Diluted shares | 42.8M | 20.6M | 11.3M | 11.3M | 11.2M | 7.2M | 2.6M | 452,555 | 431,858.15 | 414,044.975 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $49.66M | $163.54M | $40.33M | $24.87M | $36.47M | $169.39M | $564.0K | $5.55M | $21.17M | $36.39M |
| Short-term investments | $105.90M | $7.49M | $25.99M | $60.24M | $55.51M | - | - | - | - | - |
| Current assets | $159.50M | $172.16M | $68.70M | $86.15M | $93.11M | $169.44M | $764.0K | $23.24M | $43.48M | $42.76M |
| Goodwill | - | - | - | - | $29.52M | $29.52M | - | - | - | - |
| Total assets | $209.47M | $181.45M | $78.95M | $113.29M | $172.60M | $203.16M | $1.22M | $23.52M | $43.98M | $43.52M |
| Current liabilities | $10.94M | $10.96M | $6.15M | $5.74M | $4.30M | $2.92M | $3.35M | $3.08M | $9.24M | $5.08M |
| Short-term debt | - | - | - | - | $0 | $0 | - | - | - | - |
| Total liabilities | $13.06M | $14.32M | $10.63M | $11.21M | $10.68M | $3.91M | $3.35M | $3.08M | $9.24M | $5.08M |
| Shareholders' equity | $196.41M | $167.13M | $68.32M | $102.08M | $161.91M | $199.24M | -$2.13M | $4.78M | $34.74M | $38.44M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$56.37M | -$35.81M | -$37.56M | -$26.46M | -$34.50M | -$23.41M | -$5.01M | -$23.23M | -$22.35M | -$23.69M |
| Capital expenditures | $94.0K | $63.0K | $45.0K | $120.0K | $596.0K | $884.0K | $475.0K | $119.0K | $35.0K | $271.0K |
| Free cash flow | -$56.46M | -$35.87M | -$37.60M | -$26.58M | -$35.10M | -$24.29M | -$5.49M | -$23.35M | -$22.39M | -$23.96M |
| Investing cash flow | -$139.49M | $19.16M | $53.11M | $14.95M | -$98.19M | $2.83M | -$475.0K | $18.43M | -$16.10M | $19.92M |
| Financing cash flow | $82.72M | $139.87M | -$91.0K | -$90.0K | -$228.0K | $189.40M | $500.0K | $2.98M | $23.05M | $208.0K |
| Share repurchases | - | - | $91.0K | $90.0K | $228.0K | - | - | - | - | - |
| Stock-based compensation | $3.83M | $4.13M | $6.09M | $6.69M | $10.36M | $9.75M | $424.0K | $3.43M | $3.23M | $3.34M |
| Depreciation and amortization | - | - | - | - | - | - | - | - | - | $123.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -29.2% | -26.7% | -59.2% | -64.6% | -29.2% | -17.1% | - | -433.8% | -86.3% | -74.2% |
| Return on assets | -27.4% | -24.6% | -51.2% | -58.2% | -27.4% | -16.7% | -640.2% | -88.1% | -68.1% | -65.5% |
| Current ratio | 14.58 | 15.71 | 11.17 | 15.01 | 21.66 | 58.13 | 0.23 | 7.55 | 4.71 | 8.42 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $16.80M | $16.95M | $13.56M | $13.12M | $9.59M | $10.77M | $9.15M | $9.50M | $8.07M | $6.39M | $7.75M | $6.38M |
| Selling, general and admin | $6.35M | $6.37M | $6.07M | $5.96M | $5.17M | $5.82M | $4.98M | $4.81M | $4.26M | $4.27M | $4.10M | $4.66M |
| Operating income | -$23.15M | -$23.32M | -$19.63M | -$19.08M | -$14.76M | -$16.59M | -$14.12M | -$14.31M | -$12.33M | -$10.66M | -$11.85M | -$11.04M |
| Net income | -$21.69M | -$21.67M | -$17.78M | -$17.31M | -$13.26M | -$14.96M | -$11.91M | -$12.77M | -$11.22M | -$9.51M | -$11.10M | -$10.22M |
| EPS, basic | -$0.35 | -$0.36 | -$0.31 | -$0.39 | -$0.31 | -$0.35 | -$0.29 | - | -$0.50 | -$0.45 | -$0.97 | -$0.90 |
| EPS, diluted | -$0.35 | -$0.36 | -$0.31 | -$0.39 | -$0.31 | -$0.35 | -$0.29 | - | -$0.50 | -$0.45 | -$0.97 | -$0.90 |
| Diluted shares | 62.9M | 61.0M | 57.5M | - | 42.3M | 42.3M | 40.7M | - | 22.3M | 21.2M | 11.4M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $25.15M | $17.08M | $14.74M | $49.66M | $13.30M | $32.24M | $92.21M | $163.54M | $52.50M | $90.33M | $52.98M | $40.33M |
| Short-term investments | $101.90M | $125.42M | $121.05M | $105.90M | $120.12M | $90.72M | $32.90M | $7.49M | $29.74M | - | $2.99M | $25.99M |
| Current assets | $129.67M | $146.15M | $140.00M | $159.50M | $135.64M | $125.09M | $126.53M | $172.16M | $85.08M | $92.21M | $57.91M | $68.70M |
| Total assets | $156.54M | $176.09M | $191.92M | $209.47M | $144.64M | $156.93M | $168.56M | $181.45M | $94.09M | $101.65M | $68.13M | $78.95M |
| Current liabilities | $14.39M | $13.32M | $8.92M | $10.94M | $9.91M | $9.76M | $7.02M | $10.96M | $8.64M | $5.65M | $5.50M | $6.15M |
| Total liabilities | $15.52M | $14.78M | $10.71M | $13.06M | $12.35M | $12.51M | $10.07M | $14.32M | $12.30M | $9.60M | $9.73M | $10.63M |
| Shareholders' equity | $141.02M | $161.31M | $181.21M | $196.41M | $132.29M | $144.42M | $158.48M | $167.13M | $81.79M | $92.05M | $58.41M | $68.32M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.44M | -$15.39M | -$21.34M | -$16.95M | -$12.45M | -$12.25M | -$14.71M | -$9.31M | -$8.43M | -$7.69M | -$10.38M | -$8.70M |
| Capital expenditures | $723.0K | - | - | $24.0K | $4.0K | $22.0K | $44.0K | $0 | $8.0K | - | - | $0 |
| Free cash flow | -$19.16M | - | - | -$16.97M | -$12.46M | -$12.27M | -$14.76M | -$9.31M | -$8.44M | - | - | -$8.70M |
| Investing cash flow | $26.10M | $17.75M | -$14.72M | -$26.91M | -$6.51M | -$47.72M | -$58.35M | $22.50M | -$29.39M | $2.94M | $23.10M | $14.52M |
| Financing cash flow | $412.0K | -$26.0K | $1.14M | $80.96M | $13.0K | $8.0K | $1.73M | $97.85M | $0 | $42.09M | -$76.0K | $0 |
| Share repurchases | - | - | - | - | - | - | - | - | - | - | $76.0K | $0 |
| Stock-based compensation | $1.59M | $1.38M | $1.36M | $1.04M | $1.05M | $903.0K | $833.0K | $904.0K | $931.0K | $1.06M | $1.23M | $1.45M |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 9.01 | 10.97 | 15.69 | 14.58 | 13.69 | 12.82 | 18.03 | 15.71 | 9.85 | 16.33 | 10.53 | 11.17 |
Source: XBRL data Protara Therapeutics Inc. files with the SEC, latest filing dated Nov 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-40, first reported Mar 20, 2020.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
TARA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| TARA | - | - | -$78.44M | - | $148.3M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
TARA FAQ
5 questionsIs TARA profitable?
No. Protara Therapeutics Inc. reported a net loss of $78.44M for the twelve months ended Sep 30, 2026.How much cash and debt does TARA have?
Protara Therapeutics Inc. reported $25.15M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is TARA earnings per share?
Diluted earnings per share were -$1.41 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did TARA last report financial results?
The latest statements here come from Protara Therapeutics Inc.'s 10-Q filed on Nov 6, 2026, covering the period ended Sep 30, 2026.Where does this TARA financial data come from?
Quantisnow builds these statements from the structured XBRL data Protara Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.